LOXL2 and gastric cancer: Specifically, TRIM44 mediated the ubiquitination and subsequent degradation of Lysyl Oxidase Like 2 (LOXL2), thus impacting extracellular matrix remodeling and influencing tumor immunity in gastric cancer.